KR20170027868A - 조직 보호 펩티드 및 이의 용도 - Google Patents

조직 보호 펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20170027868A
KR20170027868A KR1020177005579A KR20177005579A KR20170027868A KR 20170027868 A KR20170027868 A KR 20170027868A KR 1020177005579 A KR1020177005579 A KR 1020177005579A KR 20177005579 A KR20177005579 A KR 20177005579A KR 20170027868 A KR20170027868 A KR 20170027868A
Authority
KR
South Korea
Prior art keywords
peptide
tissue protective
amino acid
seq
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177005579A
Other languages
English (en)
Korean (ko)
Inventor
안토니 세라미
마이클 브린스
토마스 콜만
Original Assignee
아라임 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아라임 파마슈티칼즈, 인크. filed Critical 아라임 파마슈티칼즈, 인크.
Publication of KR20170027868A publication Critical patent/KR20170027868A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
KR1020177005579A 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도 Ceased KR20170027868A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US60/705,741 2005-08-05
US70627605P 2005-08-08 2005-08-08
US60/706,276 2005-08-08
US83173706P 2006-07-18 2006-07-18
US60/831,737 2006-07-18
PCT/US2006/031061 WO2007019545A2 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016015A Division KR101713368B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016750A Division KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20170027868A true KR20170027868A (ko) 2017-03-10

Family

ID=37728020

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020177005579A Ceased KR20170027868A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020137016015A Expired - Fee Related KR101713368B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187030050A Ceased KR20180116475A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187016750A Ceased KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020197019568A Ceased KR20190084136A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020087005373A Expired - Fee Related KR101626153B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020207016998A Ceased KR20200072568A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020137016015A Expired - Fee Related KR101713368B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187030050A Ceased KR20180116475A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020187016750A Ceased KR20180067735A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020197019568A Ceased KR20190084136A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020087005373A Expired - Fee Related KR101626153B1 (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도
KR1020207016998A Ceased KR20200072568A (ko) 2005-08-05 2006-08-07 조직 보호 펩티드 및 이의 용도

Country Status (25)

Country Link
US (7) US8071554B2 (cg-RX-API-DMAC7.html)
EP (5) EP1924276A4 (cg-RX-API-DMAC7.html)
JP (6) JP5274253B2 (cg-RX-API-DMAC7.html)
KR (7) KR20170027868A (cg-RX-API-DMAC7.html)
CN (2) CN101378772B (cg-RX-API-DMAC7.html)
AU (1) AU2006278264B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0614529A8 (cg-RX-API-DMAC7.html)
CA (3) CA2982909A1 (cg-RX-API-DMAC7.html)
DK (3) DK2540309T3 (cg-RX-API-DMAC7.html)
EA (1) EA015672B1 (cg-RX-API-DMAC7.html)
ES (3) ES2653864T3 (cg-RX-API-DMAC7.html)
HU (3) HUE026444T2 (cg-RX-API-DMAC7.html)
IL (3) IL189287A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02050A (cg-RX-API-DMAC7.html)
LT (2) LT2594279T (cg-RX-API-DMAC7.html)
MX (3) MX339613B (cg-RX-API-DMAC7.html)
NO (1) NO20081112L (cg-RX-API-DMAC7.html)
NZ (1) NZ565937A (cg-RX-API-DMAC7.html)
PL (3) PL2371855T3 (cg-RX-API-DMAC7.html)
PT (3) PT2594279T (cg-RX-API-DMAC7.html)
SG (2) SG2014007868A (cg-RX-API-DMAC7.html)
SI (3) SI2371855T1 (cg-RX-API-DMAC7.html)
UA (1) UA100222C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007019545A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201101890B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP1924276A4 (en) * 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
CN101460188B (zh) * 2006-06-07 2013-09-04 国立大学法人德岛大学 使用促红细胞生成素的局部缺血疾病的治疗
DK2081956T3 (da) * 2006-11-13 2013-06-24 Charite Universitaetsmedizin FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012051581A2 (en) * 2010-10-14 2012-04-19 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
EP2736530B1 (en) * 2011-07-27 2018-06-06 Neumedicines, Inc Use of il-12 to generate endogenous erythropoietin
US20140249573A1 (en) * 2011-09-20 2014-09-04 A.A. Cash Technology Ltd. Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105968172A (zh) * 2014-06-22 2016-09-28 马恒标 组织保护活性多肽sl2及其应用
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
ES2952448T3 (es) 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
CN110475786A (zh) * 2017-02-27 2019-11-19 大邱庆北科学技术院 红细胞生成素衍生肽通过其对预防细胞损伤的作用的用途
WO2018157773A1 (zh) 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
US20210244791A1 (en) * 2018-04-08 2021-08-12 Brim Biotechnology, Inc. Application of pedf-derived short peptides in tendon healing
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) * 2022-12-27 2025-07-11 上海瑞吉康生物医药有限公司 相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
BR9609006A (pt) * 1995-06-07 1999-12-14 Ortho Pharma Corp Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
WO2001083548A1 (en) * 2000-04-28 2001-11-08 Effector Cell Institute Novel derivative of cell chemotactic factor
AU3323002A (en) * 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP2004522445A (ja) * 2001-02-06 2004-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 低減された免疫原性を有する修飾されたエリスロポエチン(epo)
JP2005503127A (ja) * 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
ZA200505423B (en) 2002-09-09 2008-08-27 Warren Pharmaceuticals Inc Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2006512300A (ja) * 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Hla結合ペプチド及びその使用
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
ATE482713T1 (de) * 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1924276A4 (en) 2005-08-05 2009-07-22 Araim Pharmaceuticals Inc Antiperspirant peptides and their uses
ATE554186T1 (de) 2007-11-29 2012-05-15 Molecular Health Gmbh Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2297182A4 (en) * 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Also Published As

Publication number Publication date
US9340598B2 (en) 2016-05-17
JP6158235B2 (ja) 2017-07-05
JP2013126995A (ja) 2013-06-27
HUE026444T2 (en) 2016-05-30
EP2594279A1 (en) 2013-05-22
US20190016769A1 (en) 2019-01-17
EP2594279B1 (en) 2017-11-22
US8716245B2 (en) 2014-05-06
HUE035793T2 (en) 2018-05-28
KR20180116475A (ko) 2018-10-24
KR20180067735A (ko) 2018-06-20
EP2371855B1 (en) 2015-07-22
AU2006278264B2 (en) 2012-12-06
JP2015134772A (ja) 2015-07-27
IN2014CN02050A (cg-RX-API-DMAC7.html) 2015-05-29
CA2618396C (en) 2018-02-27
US20140323401A1 (en) 2014-10-30
KR101713368B1 (ko) 2017-03-07
HK1127751A1 (en) 2009-10-09
EA015672B1 (ru) 2011-10-31
ES2653790T3 (es) 2018-02-08
SG10201805825SA (en) 2018-08-30
IL189287A0 (en) 2008-06-05
KR101626153B1 (ko) 2016-06-01
UA100222C2 (uk) 2012-12-10
PL2594279T3 (pl) 2018-03-30
BRPI0614529A8 (pt) 2016-07-12
KR20080064800A (ko) 2008-07-09
CN103724418B (zh) 2018-03-06
EP2540309B1 (en) 2017-11-22
HUE035655T2 (en) 2018-05-28
CN101378772A (zh) 2009-03-04
MX364100B (es) 2019-04-12
WO2007019545A3 (en) 2008-10-02
JP2009508471A (ja) 2009-03-05
CA2982909A1 (en) 2007-02-15
JP2020078317A (ja) 2020-05-28
LT2594279T (lt) 2018-01-10
ZA201101890B (en) 2012-12-27
EP3363451A1 (en) 2018-08-22
US20150152156A1 (en) 2015-06-04
SI2371855T1 (sl) 2015-11-30
MX2008001509A (es) 2008-04-04
SG2014007868A (en) 2014-05-29
EP2540309A3 (en) 2013-05-29
WO2007019545A2 (en) 2007-02-15
KR20200072568A (ko) 2020-06-22
ES2653864T3 (es) 2018-02-09
US20120142595A1 (en) 2012-06-07
NZ565937A (en) 2011-09-30
EP2540309A2 (en) 2013-01-02
PT2540309T (pt) 2017-12-29
LT2540309T (lt) 2018-01-10
US10100096B2 (en) 2018-10-16
JP5918155B2 (ja) 2016-05-18
PL2371855T3 (pl) 2015-12-31
PL2540309T3 (pl) 2018-03-30
IL239695A0 (en) 2015-08-31
JP2016196480A (ja) 2016-11-24
US20090221482A1 (en) 2009-09-03
PT2371855E (pt) 2015-11-03
AU2006278264A1 (en) 2007-02-15
US8071554B2 (en) 2011-12-06
US20120264682A1 (en) 2012-10-18
EA200800536A1 (ru) 2009-02-27
IL261346A (en) 2018-10-31
MX339613B (es) 2016-06-02
JP5274253B2 (ja) 2013-08-28
DK2594279T3 (en) 2018-01-08
DK2540309T3 (en) 2018-01-08
CN103724418A (zh) 2014-04-16
BRPI0614529A2 (pt) 2011-08-09
EP2371855A1 (en) 2011-10-05
US20160244498A1 (en) 2016-08-25
NO20081112L (no) 2008-05-05
DK2371855T3 (en) 2015-09-21
US8673861B2 (en) 2014-03-18
JP2018134084A (ja) 2018-08-30
PT2594279T (pt) 2017-12-29
JP6491621B2 (ja) 2019-03-27
CN101378772B (zh) 2013-12-04
CA2618396A1 (en) 2007-02-15
IL189287A (en) 2015-07-30
CA3079319A1 (en) 2007-02-15
EP1924276A2 (en) 2008-05-28
KR20130080481A (ko) 2013-07-12
KR20190084136A (ko) 2019-07-15
SI2540309T1 (en) 2018-04-30
SI2594279T1 (en) 2018-04-30
ES2550055T3 (es) 2015-11-04
EP1924276A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
KR101713368B1 (ko) 조직 보호 펩티드 및 이의 용도
AU2013201291B2 (en) Tissue protective peptides and uses thereof
AU2020201658A1 (en) Tissue protective peptides and uses thereof
HK1261413A1 (en) Tissue protective peptides and uses thereof
HK1196622A (en) Tissue protective peptides and uses thereof
HK1127751B (en) Tissue protective peptides and uses thereof
HK1185546B (en) Tissue protective peptides and uses thereof
HK1196622B (en) Tissue protective peptides and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170227

Application number text: 1020137016015

Filing date: 20130620

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170329

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170609

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180213

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170609

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20180514

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180213

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190627

Appeal identifier: 2018101002079

Request date: 20180514

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180612

Application number text: 1020137016015

Filing date: 20130620

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20180612

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20180514

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20171010

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20170329

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002079; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180514

Effective date: 20190627

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190627

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180514

Decision date: 20190627

Appeal identifier: 2018101002079

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190724

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20190724

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2018101002079

Request date: 20180514

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190627

WITB Written withdrawal of application